+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study



Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study



Experimental and Therapeutic Medicine 11(4): 1194-1200



Liraglutide (LIRA) treatment is associated with the dose-dependent reduction of weight. Higher doses are more effective than lower doses, although higher doses are also more poorly tolerated. Metformin may enhance the weight-lowering potential of LIRA via the stimulatory modulation of incretin in addition to its direct beneficial effects in PCOS. The aim of the present study was to evaluate whether metformin as an adjunct to low-dose LIRA affects body weight with increased efficacy compared with low-dose LIRA alone in obese patients with PCOS. In a 12-week study, 44 obese women with PCOS were randomly offered either combined treatment (COMBO) with 1,000 mg metformin twice a day and 1.2 mg LIRA once a day, or treatment with 1.2 mg LIRA alone. The primary outcome of treatment was an alteration in the levels of obesity. A total of 43 patients [aged 30.3±4.4 years; body mass index (BMI) 37.2±4.5 kg/m2; mean ± standard deviation] completed the study. The subjects treated with COMBO lost on average 6.2±2.4 kg compared with a 3.8±3.5 kg weight loss in the patients treated with LIRA alone (P=0.024). The BMI decreased by 2.2±0.8 kg/m2 in patients treated with COMBO and by 1.4±1.2 kg/m2 in patients treated with LIRA alone (P=0.024). A clinically significant ≥5% weight reduction was achieved in 59.1% of patients treated with COMBO and 42.9% of patients treated with LIRA alone. Reductions in glucose levels following oral glucose tolerance testing, as well as in androstenedione levels in the COMBO group were significantly greater compared with those in the LIRA group. The side effects were mild and transient in the two treatment groups. A combination of metformin and low-dose LIRA was more effective than low-dose LIRA alone in reducing body weight in obese patients with PCOS.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058302740

Download citation: RISBibTeXText

PMID: 27073422

DOI: 10.3892/etm.2016.3081


Related references

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. European Journal of Endocrinology 170(3): 451-459, 2014

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. Bmc Endocrine Disorders 17(1): 5, 2017

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study. Metabolic Syndrome and Related Disorders 15(10): 515-520, 2017

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocrine Connections 6(2): 89-99, 2017

The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Frontiers in Endocrinology 5: 140, 2014

A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones 14(1): 81-90, 2016

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. Journal of Ovarian Research 8: 32, 2015

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obesity and Metabolism 20(1): 215-218, 2018

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. Bmc Endocrine Disorders 15: 14, 2015

Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocrine Research 40(3): 133-138, 2015

Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reproductive Biomedicine Online 35(1): 121-127, 2017

Dpp4 Inhibitor Sitagliptin as a Potential Treatment Option in Metformin-Intolerant Obese Women with Polycystic Ovary Syndrome: a Pilot Randomized Study. Endocrine Practice 24(1): 69-77, 2018

Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clinical Endocrinology 86(5): 725-730, 2017

Liraglutide in polycystic ovary syndrome. Medicina Clinica 143(6): 283-284, 2014

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clinical Endocrinology 81(4): 523-528, 2014